MET and alveolar soft part sarcoma: Tyrosine kinase inhibitors (TKIs) targeting VEGFR and MET, including pazopanib, sunitinib, and cediranib, have demonstrated encouraging results in advanced ASPS, frequently resulting in disease stabilization or partial responses (2, 3).